Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNG908 in MTAP-deleted Advanced or Metastatic Solid Tumors
2024-511976-34-00Phase 2Completed
- Sponsor
- Tango Therapeutics
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of TNG908 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), mesothelioma and 5 more, sponsored by Tango Therapeutics. Primary endpoints: Dose-limiting toxicities (DLTs) incidence (Phase 1), Objective response rate (ORR) (Phase 2) and 3 more. Started Oct 2024; status: completed.
02
Drugs
TNG908
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)mesotheliomaBone and soft tissue sarcomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-511976-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511976-34-00.